news
BMS presents new data for Opdivo at ASCO
6 June 2016 | By Victoria White, Digital Content Producer
New data for Bristol-Myers Squibb’s Opdivo has been presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO)...
List view / Grid view
Oncology
news
Daratumumab extends PFS in patients with multiple myeloma
6 June 2016 | By Victoria White, Digital Content Producer
Daratumumab, in combination with bortezomib and dexamethasone, demonstrated a 61% reduction in the risk of disease progression or death...
article
Boehringer Ingelheim at ASCO: Oncology and Innovation
6 June 2016 | By Victoria White, Digital Content Producer
We recently caught up with Dr Jörg Barth, Boehringer Ingelheim, to find out more about the company’s oncology pipeline and presence at ASCO....
news
Immunotherapy shrinks tumours in neuroblastoma patients
3 June 2016 | By Victoria White, Digital Content Producer
Neuroblastoma tumours shrank in 80% of young, high-risk patients enrolled in a Phase II clinical trial that included an experimental monoclonal antibody...
news
Data support Opdivo as new standard of care in mRCC, says GlobalData
1 June 2016 | By Victoria White, Digital Content Producer
New data strengthen the body of research into Opdivo, hailing it as the new standard of care in recurrent metastatic renal cell carcinoma (mRCC)...
news
Stomach cancer with copies of FGFR2 gene more susceptible to AZD4547
27 May 2016 | By Victoria White, Digital Content Producer
Scientists are able to identify patients with stomach cancer who are most likely to respond to AZD4547 by measuring copies of the FGFR2 gene in the bloodstream...
news
EC approves eribulin for the treatment of advanced liposarcoma
5 May 2016 | By Victoria White, Digital Content Producer
Eribulin is approved for those patients who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease...
article
Inhibition of mutant P53 tumour cells by medicinal plants
4 May 2016 | By Osuntokun Oludare Temitope and Ogunleye Adewale Joseph, Adekunle Ajasin University
The aetiology of tumours is attributed to changes in many internal (molecular) factors, most of which include mutations in several regulatory mechanisms and the loss of cell differentiation. Human isoforms of the p53 protein play a key role in maintaining genetic stability, functioning as active tumour suppressors. However, a mutation…
article
From HIV to oncology: widening access through flexible IP
28 April 2016 | By Jon Pender, VP Government Affairs, GSK
Jon Pender, GSK, discusses how a flexible and thoughtful approach to IP can help get medicines to the poorest and hardest-to-reach patients around the world...
news
Immuno-oncology market to hit $34 billion by 2024, says GlobalData
19 April 2016 | By Victoria White, Digital Content Producer
The total immuno-oncology market will be worth approximately $14 billion by 2019, rising to $34 billion by 2024, according to GlobalData...
news
Children with cancer to be offered gene testing in personalised treatment initiative
31 March 2016 | By Victoria White
Children with cancer will be offered testing for genetic mutations in their tumours as part of an initiative to personalise children’s cancer treatment...
news
Vaxon completes enrolment in Phase IIb trial of Vx-001 in NSCLC
16 March 2016 | By Victoria White
Vx-001 is a therapeutic cancer vaccine based on proprietary antigens known as optimised cryptic tumour peptides...
news
Peptide vaccines and immuno-oncology products hold promise in glioblastoma
15 March 2016 | By Victoria White
According to GlobalData analysts, hopes for improved therapies for glioblastoma have turned to Opdivo and drugs combining peptide vaccines with immuno-oncology products...
news
Forecasting in dynamic Oncology Markets
14 March 2016 | By Black Swan Analysis
Two big things struck me as interesting during an Innovations in Oncology Conference in Edinburgh this month...
news
Lenvatinib approved in Israel for patients with advanced thyroid cancer
9 March 2016 | By Victoria White
From today, people in Israel with radioactive iodine refractory differentiated thyroid cancer will have access to Eisai’s Lenvima (lenvatinib)...
